Open AccessSMAC exhibits anti-tumor effects in ECA109 cells by regulating expression of inhibitor of apoptosis protein family
Author(s) -
Ning Jiang,
Weiquan Zhang,
Hong Dai,
Yingjie Hao,
Liming Zhang,
Lei Shan,
Xiaodong Yang,
Chuanliang Peng
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i19.5019
Subject(s) - medicine , apoptosis , bcl 2 family , inhibitor of apoptosis , cancer research , protein expression , protein family , microbiology and biotechnology , programmed cell death , genetics , gene , biology
The poor prognosis and rising incidence of esophageal cancer highlight the need for improved therapeutics that are essential prior to treatment. LCL161 is an SMAC (second mitochondrial activator of caspases) mimic and inhibitor of apoptosis protein (IAP) antagonist which exhibits anti-tumor effects and improves the chemical sensitivity of many cancers.